AF
ITRM

Apollon Financial’s Iterum Therapeutics ITRM Stock Holding History

Apollon Financial’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-630,250
Closed -$211K – 267
2025
Q4 		$211K Buy
630,250
+380,000
+152% +$205K 0.03% 248
2025
Q3 		$168K Hold
250,250
– – 0.03% 223
2025
Q2 		$249K Hold
250,250
– – 0.05% 192
2025
Q1 		$308K Hold
250,250
– – 0.07% 169
2024
Q4 		$443K Buy
250,250
+25,500
+11% +$40K 0.11% 124
2024
Q3 		$245K Hold
224,750
– – 0.07% 150
2024
Q2 		$257K Hold
224,750
– – 0.08% 126
2024
Q1 		$346K Buy
224,750
+24,750
+12% +$40.2K 0.12% 110
2023
Q4 		$394K Buy
+200,000
New +$248K 0.16% 96

Other funds holding ITRM

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
GWP
Gen-Wealth Partners Zeeland, Michigan $360M AUM 27.44% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Apollon Financial's ITRM Position: Q1 2026 in Review

Apollon Financial sold out of Iterum Therapeutics (ITRM) in Q1 2026, closing a stake of 630,250 shares — an estimated $211K sold.

Apollon Financial first reported a position in ITRM in Q4 2023 and held it in 9 quarters. The position peaked at $443K in Q4 2024. 18 funds tracked by Wall St. Rank hold ITRM as of Q1 2026.

  • Apollon Financial reported no remaining Iterum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Apollon Financial sold 630,250 Iterum Therapeutics shares in Q1 2026, an estimated $211K.
  • Apollon Financial first reported a position in Iterum Therapeutics in Q4 2023 and held it in 9 quarters.
  • Apollon Financial's Iterum Therapeutics position peaked at $443K in Q4 2024.
  • 18 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q1 2026.

Based on Apollon Financial's 13F filing for Q1 2026, filed 22 Apr 2026.